Increasing unusual option volume: TERN XLB BKLN GROY HIMX BIZD ADMA

Fri, 13 Mar 2026 11:18:23 -0400

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Wed, 25 Feb 2026 16:05:00 -0400

FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March.

TD Cowen's 46^th Annual Health Care Conference
Format: Fireside Chat
Date and Time: Monday, March 2, 2026 at 3:50 p.m. ET
Location: Boston, MA

Leerink Global Healthcare Conference
Format: Fireside Chat
Date and Time: Monday, March 9, 2026 at 1:40 p.m. ET
Location: Miami, FL

Barclays 28^th Annual Global Healthcare Conference

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Wed, 25 Feb 2026 16:05:00 -0400

TD Cowen's 46^th Annual Health Care Conference
Format: Fireside Chat
Date and Time: Monday, March 2, 2026 at 3:50 p.m. ET
Location: Boston, MA

Leerink Global Healthcare Conference
Format: Fireside Chat
Date and Time: Monday, March 9, 2026 at 1:40 p.m. ET
Location: Miami, FL

Barclays 28^th Annual Global Healthcare Conference

Form 4 Terns Pharmaceuticals, For: Feb 17 Filed by: Burroughs Amy L.

Wed, 18 Feb 2026 19:01:00 -0400

si-local-file:///var/storage/secattach/20260218/26024246.html

Form 4 Terns Pharmaceuticals, For: Feb 17 Filed by: Burroughs Amy L.

Wed, 18 Feb 2026 19:01:00 -0400

si-local-file:///var/storage/secattach/20260218/26024246.html

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Commodore Capital LP

Tue, 17 Feb 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260217/26013671.html

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Commodore Capital LP

Tue, 17 Feb 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260217/26013671.html

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 13 Feb 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260213/26002440.html

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 13 Feb 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260213/26002440.html

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Deep Track Capital, LP

Fri, 13 Feb 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260213/25996279.html

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Deep Track Capital, LP

Fri, 13 Feb 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260213/25996279.html

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Soleus Capital Master Fund, L.P.

Thu, 12 Feb 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260212/25993197.html

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Soleus Capital Master Fund, L.P.

Thu, 12 Feb 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260212/25993197.html

Form SCHEDULE 13G Terns Pharmaceuticals, Filed by: Adage Capital Management, L.P.

Thu, 12 Feb 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260212/25988602.html

Form SCHEDULE 13G Terns Pharmaceuticals, Filed by: Adage Capital Management, L.P.

Thu, 12 Feb 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260212/25988602.html

Leerink Partners Starts Terns Pharmaceuticals (TERN) at Outperform

Mon, 09 Feb 2026 06:23:25 -0400

Leerink Partners initiates coverage on Terns Pharmaceuticals (NASDAQ: TERN) with a Outperform rating and a price target of $58.00.

The analyst comments "Bottom Line: We are initiating coverage of Terns Pharmaceuticals (TERN) with an Outperform rating and $58 price target. TERN is a clinical-stage biotechnology company developing TERN-701, a next-generation allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia (CML) — a large, validated market with well-established targeted therapy adoption. TERN-701 builds on the clinical and commercial success of allosteric inhibition established by NVS's (Not Rated) Scemblix (asciminib), a drug on a $1.6bn run rate as of 4Q25. Early phase 1 TERN-701 CARDINAL

Leerink Partners Starts Terns Pharmaceuticals (TERN) at Outperform

Mon, 09 Feb 2026 06:23:25 -0400

Leerink Partners initiates coverage on Terns Pharmaceuticals (NASDAQ: TERN) with a Outperform rating and a price target of $58.00.

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Turner Heather D

Mon, 02 Feb 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260202/25932321.html

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Turner Heather D

Mon, 02 Feb 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260202/25932321.html

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Azelby Robert

Mon, 02 Feb 2026 18:07:00 -0400

si-local-file:///var/storage/secattach/20260202/25932319.html

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Azelby Robert

Mon, 02 Feb 2026 18:07:00 -0400

si-local-file:///var/storage/secattach/20260202/25932319.html

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Tripuraneni Radhika

Mon, 02 Feb 2026 18:07:00 -0400

si-local-file:///var/storage/secattach/20260202/25932320.html

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Tripuraneni Radhika

Mon, 02 Feb 2026 18:07:00 -0400

si-local-file:///var/storage/secattach/20260202/25932320.html

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: KINDLER JEFFREY B

Mon, 02 Feb 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260202/25932316.html

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: KINDLER JEFFREY B

Mon, 02 Feb 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260202/25932316.html

StreetInsider.com News Articles

Increasing unusual option volume: TERN XLB BKLN GROY HIMX BIZD ADMA

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Form 4 Terns Pharmaceuticals, For: Feb 17 Filed by: Burroughs Amy L.

Form 4 Terns Pharmaceuticals, For: Feb 17 Filed by: Burroughs Amy L.

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Commodore Capital LP

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Commodore Capital LP

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Vivo Opportunity Fund Holdings, L.P.

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Vivo Opportunity Fund Holdings, L.P.

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Deep Track Capital, LP

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Deep Track Capital, LP

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Soleus Capital Master Fund, L.P.

Form SCHEDULE 13G/A Terns Pharmaceuticals, Filed by: Soleus Capital Master Fund, L.P.

Form SCHEDULE 13G Terns Pharmaceuticals, Filed by: Adage Capital Management, L.P.

Form SCHEDULE 13G Terns Pharmaceuticals, Filed by: Adage Capital Management, L.P.

Leerink Partners Starts Terns Pharmaceuticals (TERN) at Outperform

Leerink Partners Starts Terns Pharmaceuticals (TERN) at Outperform

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Turner Heather D

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Turner Heather D

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Azelby Robert

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Azelby Robert

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Tripuraneni Radhika

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: Tripuraneni Radhika

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: KINDLER JEFFREY B

Form 4 Terns Pharmaceuticals, For: Feb 01 Filed by: KINDLER JEFFREY B